Hydroxyurea therapy for neurological and cognitive protection in pediatric sickle cell anemia in Uganda (BRAIN SAFE II): Protocol for a single-arm open label trial

Hydroxyurea therapy for neurological and cognitive protection in pediatric sickle cell anemia in Uganda (BRAIN SAFE II): Protocol for a single-arm open label trial

Background: Children with sickle cell anemia (SCA) in Sub-Saharan Africa are at high risk of sickle cerebrovascular injury (SCVI). Hydroxyurea, a commonly used disease-modifying therapy, may reduce SCVI resulting in potential impact on reducing stroke and cognitive dysfunction. We aim to test the im...

Full description

Saved in:
Bibliographic Details
Main Authors: Vincent Mboizi, Catherine Nabaggala, Deogratias Munube, John M. Ssenkusu, Phillip Kasirye, Samson Kamya, Michael G. Kawooya, Amelia Boehme, Frank Minja, Ezekiel Mupere, Robert Opoka, Caterina Rosano, Richard Idro, Nancy S. Green
Format: Article
Language:English
Published: Elsevier 2024-12-01
Series:Contemporary Clinical Trials Communications
Subjects:
Hydroxyurea
Sickle cell anemia
Neurological and cognitive protection
Transcranial Doppler
Online Access:http://www.sciencedirect.com/science/article/pii/S2451865424001510
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items